According to a recent LinkedIn post from Plexāā | Creators of BLOOM⁴³, the company plans to participate in The Aesthetic Society’s Aesthetic Meet 2026 in May. The post notes that CEO and founder Dr. Saahil Mehta and U.S. patient champion Nichole Wenderlich Owens, MBA, intend to engage with clinicians at the event.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights a focus on pre‑surgical preparation and its potential role in improving patient outcomes, particularly in breast surgery and broader patient care. For investors, this suggests an emphasis on clinician education, relationship building, and validation of its medtech offering within a specialized aesthetic surgery audience.
The post also indicates that Plexāā is open to one‑on‑one meetings at the conference via direct contact, implying a targeted business development effort. If these interactions translate into clinical adoption or strategic partnerships, the exposure at Aesthetic Meet 2026 could support future revenue growth and strengthen the company’s positioning in the prehab and medtech segments.